Psychedeic-Chronicle-Logo

Suggestions

  • Psychedelic News
  • DMT
  • Ketamine
  • Mescaline
  • Psilocybin
  • CEO INTERVIEWS

Psychedeic-Chronicle-Logo

DMT

atai Life Sciences Announce First Subject Dosed in Synthetic DMT Phase 1 Trial Psychedeic-Chronicle-Logo-White
Psychedelic News

atai Life Sciences Announce First Subject Dosed in Synthetic DMT Phase 1 Trial

atai has administered the first dosage of their VLS-01 synthetic DMT drug in their Phase 1 single-ascending dose (SAD) trial, with topline

October 7, 2022
Biomind Labs Complete Phase II Dosing of DMT-Based BMND01 for Treatment-Resistant Depression Psychedeic-Chronicle-Logo-White
Psychedelic News

Biomind Labs Complete Phase II Dosing of DMT-Based BMND01 for Treatment-Resistant Depression

Leading psychedelic biotech company Biomind Labs Inc. (NEO: BMND) (OTC: BMNDF) (FSE: 3XI) has announced the completion of dose administration to 30

September 22, 2022
Small-Pharma-Receive-UK-Regulatory-Approval-to-Begin-DMT-Assisted-Psychotherapy-and-SSRI-Drug-Interaction-Study Psychedeic-Chronicle-Logo-White
Psychedelic News

Small Pharma Receive UK Regulatory Approval to Begin DMT-Assisted Psychotherapy and SSRI Drug Interaction Study

Psychedelic biotechnology company Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) announced today confirmation of regulatory approval from the U.K. Medicines and Healthcare

August 15, 2022
Biomind Labs Hire Former FDA Director To Oversee Psychedelic Drug Development Clinical Trials Psychedeic-Chronicle-Logo-White
Psychedelic News

Biomind Labs Hire Former FDA Director To Oversee Psychedelic Drug Development Clinical Trials

World-class psychedelic biotech firm Biomind Labs Inc. (NEO: BMND) (OTC: BMNDF) (FSE: 3XI) announced that Former FDA Director Dr. Thomas Laughren has

August 1, 2022

Recent Posts

  • Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment
  • Numinus Develop Psilocybin Mushroom Tea Bags for Psychedelic Research Use
  • atai Life Sciences Announce First Subject Dosed in Synthetic DMT Phase 1 Trial
  • Tryp Therapeutics Add 2 New Provisional Patents to Intellectual Property Portfolio
  • Biomind Labs Complete Phase II Dosing of DMT-Based BMND01 for Treatment-Resistant Depression

Recent Comments

No comments to show.

Popular

Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment

Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment

Silo Pharma (Nasdaq: SILO), a developmental-stage psychedelic biopharmaceutical firm, announced

Numinus Develop Psilocybin Mushroom Tea Bags for Psychedelic Research Use

Numinus Develop Psilocybin Mushroom Tea Bags for Psychedelic Research Use

Numinus Wellness Inc.’s (OTCQX: NUMIF) (TSX: NUMI) research division, Numinus

atai Life Sciences Announce First Subject Dosed in Synthetic DMT Phase 1 Trial

atai Life Sciences Announce First Subject Dosed in Synthetic DMT Phase 1 Trial

atai has administered the first dosage of their VLS-01 synthetic

Psychedeic-Chronicle-Logo

© 2022 PSYCHEDELIC CHRONICLE
ALL RIGHTS RESERVED.

  • Psychedelic News
  • DMT
  • Ketamine
  • Mescaline
  • Psilocybin
  • CEO INTERVIEWS